It was originally derived from a protein fragment associated with gastric juice and studied for its protective effects on the gastrointestinal system. Since its development in the 1990s, research has expanded into musculoskeletal healing, where it has shown promising effects in animal models involving tendon, ligament, muscle, and bone injuries. One important caveat regarding BPC-157 is that it is not FDA-approved for human use, and most of what we know comes from preclinical research
Lisa Hartford, MD GHK-Cu Copper Peptides: The 50-Year Research Trail, Translated A tripeptide first isolated from human plasma in 1973 has spent the last five decades quietly accumulating one of the densest peer-reviewed evidence trails in regenerative skincare
You will also find the vaccination schedules for people who are moderately or severely immunocompromised in the Immunize.org standing orders templates for administration of COVID-19 vaccines: For ages 6 months through 11 years: www.immunize.org/wp-content/uploads/catg.d/p3140a.pdf mRNA vaccines for ages 12 years and older: www.immunize.org/wp-content/uploads/catg.d/p3140.pdf Protein subunit vaccine for ages 12 years and older: www.immunize.org/wp-content/uploads/catg.d/p3141.pdf In general, people who are moderately or severely immunocompromised and previously unvaccinated are recommended to receive a 2-dose (protein subunit) or 3-dose (mRNA) initial series of COVID-19 vaccine, with an additional dose 6 months later of any age-appropriate COVID-19 brand (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty
Vial size: 10 mg
